
CLAIMS

1. A compound of formula (I)



(I)

~~or a pharmaceutically acceptable salt thereof~~,

wherein

R^1 is F, Cl, Br, OCH_3, OCH_2F, $OCHF_2$, or OCF_3;

R^2 is F, Cl, CF_3, or CN;

X is $(CH_2)_{1\text{-}2}$, CHF, CHD, CD_2 or CF_2;

Y is $(CH_2)_{0\text{-}2}$, CHF, CHD, CD_2, O, S, OCH_2 or CF_2;

Z is CH_2, CD_2, CHF, CDF, CF_2, CH(OH), CO, $CH(CH_3)$, O, or S,

wherein, when Y is O, OCH_2, or S, then Z is CH_2;

wherein, when Z is O, S, or NCH_3, then Y is $(CH_2)_{0\text{-}2}$, or CF_2;

wherein, when Z is CH(OH), then Y is CHF or CF_2;

J is CR^J;

wherein R^J is H, F, Cl, Br, CH_3, CD_3, CF_3, CHF_2, CDF_2, OCH_3 or CN;

E is CR^E or N;

wherein R^E is H, F, Cl, Br, I, CN, CH_3, CH_2CH_3, $CH(CH_3)_2$, CD_3, CHD_2, CH_2D, CHF_2, CDF_2, $C(CH_3)F_2$, $C(CD_3)F_2$, CF_3, cyclopropyl, OCH_3, OCH_2CH_2OH, OCF_3, SCH_3 or $SCHF_2$; and

G is CH or N;

in free form or in a pharmaceutically acceptable salt thereof~~form~~.

2. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^1 is F, Cl or $OCHF_2$;

R^2 is CF_3 or CN;

X is CH_2 or CHF;

Y is a $(CH_2)_{0-2}$ or CHF;

Z is CHF, CDF, CF_2, O, or S;

J is CR^J;

wherein R^J is H, F, Cl, CH_3 or CD_3;

E is CR^E or N;

wherein R^E is H, F, Br, or CF_3; and

G is CH.

3. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^1 is $OCHF_2$;

R^2 is CF_3;

X is CH_2 or CHF;

Y is $(CH_2)_{0-2}$;

Z is CF_2, or O;

J is CR^J;


wherein R^J is H, F, Cl, CH_3 or CD_3;

E is CR^E or N;

wherein R^E is H, F, Br or CF_3; and


G is CH.

4. The compound of formula (I) or a pharmaceutically acceptable salt ~~form~~ thereof according to any one of claims from 1 to 3, wherein the stereochemistry is defined as shown in formula (Ia)



(Ia).

5. The compound of formula (I) or a pharmaceutically acceptable salt ~~form~~ thereof according to any one of claims from 1 to 4, wherein the stereochemistry is defined as shown in formula (Ib)



(Ib).

6. The compound according to claim 5,

wherein

X is CH_2 or CHF;

Y is $(CH_2)_{0\text{-}2}$;

Z is O, S or CF_2;

E is CR^E or N;

wherein R^E is H, F, Br or CF_3; and

J is CR^J;

wherein R^J is H, F, Cl, CH_3 or CD_3.

7. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

(*S*)-5'-bromo-8-(difluoromethoxy)-4'-fluoro-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-8-(difluoromethoxy)-4',5'-difluoro-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-8'-(difluoromethoxy)-3,6'-bis(trifluoromethyl)-5,6-dihydro-3'*H*-spiro[cyclopenta[*c*]pyridine-7,2'-imidazo[1,2-*a*]pyridine];

(*S*)-5'-bromo-8-(difluoromethoxy)-4'-fluoro-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene]-6-carbonitrile;

(*S*)-5'-bromo-4'-fluoro-8-(fluoromethoxy)-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-8-(difluoromethoxy)-5',6-bis(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-6'-bromo-8-(difluoromethoxy)-5'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-8-(difluoromethoxy)-5'-fluoro-6-(trifluoromethyl)-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'(3'*H*)-one;

(1'*S*,3'*R*)-6'-bromo-8-(difluoromethoxy)-3',5'-difluoro-6-(trifluoromethyl)-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'(3'*H*)-one;

(1'*S*,3'*R*,4'*S*)-6'-bromo-8-(difluoromethoxy)-3',5'-difluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'-ol;

(*S*)-6'-bromo-8-(difluoromethoxy)-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-(difluoromethoxy)-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-8-(difluoromethoxy)-5'-fluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

(*S*)-6'-bromo-8-(difluoromethoxy)-4',4',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-(difluoromethoxy)-4',4',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6'-carbonitrile;

(*S*)-6'-bromo-8-chloro-5'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-8-(difluoromethoxy)-3',3',5'-trifluoro-6-(trifluoromethyl)-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'(3'*H*)-one;

(1'*S*,4'*S*)-6'-bromo-8-(difluoromethoxy)-3',3',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'-ol;

(1'*S*,4'*R*)-6'-bromo-8-(difluoromethoxy)-3',3',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'-ol;

(1'*S*,3'*R*)-8-(difluoromethoxy)-3',5'-difluoro-6-(trifluoromethyl)-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'(3'*H*)-one;

(1'*S*,3'*R*)-8-(difluoromethoxy)-3',5'-difluoro-6-(trifluoromethyl)-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'(3'*H*)-one;

(*S*)-8-(difluoromethoxy)-5'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6'-carbonitrile;

(*S*)-8-(difluoromethoxy)-4',4',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(2S,4'S)-6'-bromo-8-(difluoromethoxy)-4',5'-difluoro-3',4'-dihydro-2'H,3H-spiro[imidazo[1,2-a]pyridine-2,1'-naphthalene]-6-carbonitrile;

(1'S,4'S)-8-(difluoromethoxy)-4',5'-difluoro-6-(trifluoromethyl)-3',4'-dihydro-2'H,3H-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6'-carbonitrile;

(*S*)-8-(difluoromethoxy)-5'-fluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

d_2-(*S*)-8-(difluoromethoxy)-5'-fluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-5'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-5',6',8-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-1'-chloro-8',8'-difluoro-8-methoxy-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(S)-8-(difluoromethoxy)-8',8'-difluoro-1'-methyl-6-(trifluoromethyl)-7',8'-dihydro-3H,6'H-spiro[imidazo[1,2-a]pyridine-2,5'-isoquinoline];

(S)-8-(difluoromethoxy)-8',8'-difluoro-1'-(methyl-d3)-6-(trifluoromethyl)-7',8'-dihydro-3H,6'H-spiro[imidazo[1,2-a]pyridine-2,5'-isoquinoline];

(*S*)-8-(difluoromethoxy)-8',8'-difluoro-1'-methoxy-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(*S*)-8-(difluoromethoxy)-6'-fluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

(*S*)-1'-chloro-8-(difluoromethoxy)-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(*S*)-3'-chloro-8-(difluoromethoxy)-6-(trifluoromethyl)-6',7'-dihydro-3*H*,5'*H*-spiro[imidazo[1,2-*a*]pyridine-2,8'-isoquinoline];

(*S*)-8-(difluoromethoxy)-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6'-carbonitrile;

(*S*)-7-bromo-8'-(difluoromethoxy)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-6',7-bis(trifloromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7-chloro-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-7-bromo-8-fluoro-8'-(fluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7-chloro-8'-(difluoromethoxy)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-6',7-bis(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-7,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-7-methyl-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-8-chloro-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-7-bromo-8'-(difluoromethoxy)-8-fluoro-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]-6'-carbonitrile;

(*S*)-7-bromo-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-8'-(difluoromethoxy)-8-fluoro-7-iodo-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]-6'-carbonitrile; (*S*)-7-bromo-6'-chloro-8'-(difluoromethoxy)-8-fluoro-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-8'-chloro-6',7-bis(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7,8'-bis(difluoromethoxy)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-(difluoromethyl)-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-chloro-8-(difluoromethoxy)-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-pyrano[2,3-*c*]pyridine];

(2'*S*,3*R*)-7-bromo-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*S*)-7-bromo-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*R*)-7-bromo-8'-(difluoromethoxy)-3-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*R*)-8'-(difluoromethoxy)-3-fluoro-7-iodo-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*R*)-8'-(difluoromethoxy)-3-fluoro-6',7-bis(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*R*)-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8-(difluoromethoxy)-8'-fluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-isochroman]; (*S*)-7'-chloro-8-(difluoromethoxy)-8'-fluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochroman]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-8'-fluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochroman];

(*S*)-8-(difluoromethoxy)-8'-fluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochroman]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-8'-fluoro-6,7'-bis(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiopyrano[3,2-*c*]pyridine];

(*S*)-8-(difluoromethoxy)-8'-fluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-isothiochroman]-6-carbonitrile; (*S*)-8'-(difluoromethoxy)-9-fluoro-6'-(trifluoromethyl)-3,4-dihydro-2*H*,3'*H*-spiro[benzo[*b*]oxepine-5,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8-(difluoromethoxy)-1'-(difluoromethyl)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(*S*)-5'-bromo-4',8-dichloro-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-5'-bromo-8-(difluoromethoxy)-6-(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene];

(*S*)-8-(difluoromethoxy)-5'-iodo-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-indene]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-4'-fluoro-5',6-bis(trifluoromethyl)-2',3'-dihydro-3H-spiro[imidazo[1,2-a]pyridine-2,1'-indene];

(*S*)-8-(difluoromethoxy)-6-(trifluoromethyl)-2',3'-dihydro-3H-spiro[imidazo[1,2-a]pyridine-2,1'-indene]; (*S*)-5',8-difluoro-6'-methoxy-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-fluoro-6,6'-bis(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

rac-5',6',8-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-chloro-5'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-5'-fluoro-8-methoxy-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

rac-5'-bromo-8-(difluoromethoxy)-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-5'-chloro-8-(difluoromethoxy)-6'-fluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(2*S*,3'*R*,4'*R*)-6'-bromo-8-(difluoromethoxy)-3',4',5'-trifluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-(difluoromethoxy)-5'-fluoro-6'-methoxy-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-(difluoromethoxy)-5',6'-difluoro-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-8-(difluoromethoxy)-6,6'-bis(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

rac-8-(difluoromethoxy)-5',6-bis(trifluoromethyl)-3',4'-dihydro-2'H,3H-spiro[imidazo[1,2-a]pyridine-2,1'-naphthalene];

(*S*)-5'-chloro-8-(difluoromethoxy)-6-(trifluoromethyl)-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-6-chloro-8-(difluoromethoxy)-5'-fluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene];

(*S*)-6'-bromo-8-(difluoromethoxy)-6-(trifluoromethyl)-2',3'-dihydro-3*H*,4'*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalen]-4'-one;

(*S*)-8-(difluoromethoxy)-5',6'-difluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

(*S*)-6'-bromo-8-(difluoromethoxy)-4',4',5'-trifluoro-3',4'-dihydro-2'*H*,3*H*-spiro[imidazo[1,2-*a*]pyridine-2,1'-naphthalene]-6-carbonitrile;

rac-8-(difluoromethoxy)-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];

(*S*)-1'-chloro-8-(difluoromethoxy)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline]-6-carbonitrile;

(*S*)-8-chloro-8'-(fluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine]; (*S*)-8-chloro-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine]-7-carbonitrile;

(3*R*,4*S*)-7-chloro-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(3*R*,4*S*)-8'-(difluoromethoxy)-3,7,8-trifluoro-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-7-(methylthio)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7-bromo-8-chloro-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

rac-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7,8-dibromo-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-7-methoxy-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-6',8-bis(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-8-fluoro-7-(trifluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-7-((difluoromethyl)thio)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8-bromo-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3'*H*-spiro[chromane-4,2'-imidazo[1,2-*a*]pyridine]; *rac*-8-(difluoromethoxy)-8'-fluoro-6,7'-bis(trifluoromethyl)-3H-spiro[imidazo[1,2-a]pyridine-2,4'-isochroman];

(2S)-8-(difluoromethoxy)-8'-fluoro-3H-spiro[imidazo[1,2-a]pyridine-2,4'-thiochromane]-6-carbonitrile-2',2',3'-d3;

(*S*)-7'-bromo-8-(difluoromethoxy)-8'-fluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochromane]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-8'-fluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochromane]-7'-carbonitrile;

(*S*)-8-(difluoromethoxy)-7',8'-difluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochroman]-6-carbonitrile;

(*S*)-8-(difluoromethoxy)-7',8'-difluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochromane];

(*S*)-8'-fluoro-8-(fluoromethoxy)-6,7'-bis(trifluoromethyl)-2',3'-dihydro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiopyrano[3,2-*c*]pyridine];

(*S*)-8-(difluoromethoxy)-8'-fluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-isothiochromane];

(*S*)-8-(difluoromethoxy)-7'-fluoro-6-(trifluoromethyl)-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-isothiochromane];

(*S*)-8'-(difluoromethoxy)-8,9-difluoro-6'-(trifluoromethyl)-3,4-dihydro-2*H*,3'*H*-spiro[benzo[*b*]oxepine-5,2'-imidazo[1,2-*a*]pyridine];

rac-9-chloro-8'-(difluoromethoxy)-6'-(trifluoromethyl)-3,4-dihydro-2*H*,3'*H*-spiro[benzo[*b*]oxepine-5,2'-imidazo[1,2-*a*]pyridine]; and

(*S*)-8-chloro-8'-(difluoromethoxy)-9-fluoro-6'-(trifluoromethyl)-3,4-dihydro-1*H*,3'*H*-spiro[benzo[*c*]oxepine-5,2'-imidazo[1,2-*a*]pyridine].

8. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

(*S*)-8-(difluoromethoxy)-8'-fluoro-3*H*-spiro[imidazo[1,2-*a*]pyridine-2,4'-thiochroman]-6-carbonitrile;

(*S*)-8'-(difluoromethoxy)-9-fluoro-6'-(trifluoromethyl)-3,4-dihydro-2*H*,3'*H*-spiro[benzo[*b*]oxepine-5,2'-imidazo[1,2-*a*]pyridine];

(*S*)-8'-(difluoromethoxy)-6',7-bis(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(*S*)-7-bromo-8'-(difluoromethoxy)-8-fluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];

(2'*S*,3*R*)-8'-(difluoromethoxy)-3,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];


(*S*)-8'-(difluoromethoxy)-7,8-difluoro-6'-(trifluoromethyl)-3'*H*-spiro[chroman-4,2'-imidazo[1,2-*a*]pyridine];


(*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline];


(*S*)-8-(difluoromethoxy)-8',8'-difluoro-1'-(methyl-d_3)-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline]; and

(*S*)-8-(difluoromethoxy)-8',8'-difluoro-1'-methyl-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline].

9. A compound, or a pharmaceutically acceptable salt thereof, that is selected from the group consisting of:




,


and


.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, that is:



.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

12. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof and one or more therapeutically active agents.

13. The combination according to claim 12, wherein said therapeutic agent is selected from a mTOR inhibitor selected from Temsirolimus; Ridaforolimus; Everolimus (RAD001); Rapamycin; Simapimod; (5-{2,4-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-Amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one; N^2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4*H*-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine-; N-[4-[[[3-[(3,5-dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methyl-benzamide; or (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[1,5-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid.

14. The combination according to claim 13, wherein said mTOR inhibitor is everolimus.

~~15. A method of modulating HIF2α activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof.~~

~~16. A method of treating a disorder or disease which is a cancer, comprising administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof.~~

~~17. A method of treating according to claim 16 wherein the cancer is selected from adrenocortical carcinoma, breast cancer, clear cell renal cell carcinoma (ccRCC), colorectal cancer , germ cell tumor, glioblastoma multiforme (GBM), glioma, head and neck cancer , hepatocellular carcinoma, kidney cancer, lung cancer, malignant glioma, ocular cancer, pancreatic cancer, paraganglioma, pheochromocytoma, prostate cancer, and renal cell carcinoma, comprising~~

~~administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof.~~

~~18. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, for use as a medicament.~~

~~19. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder or disease is a cancer.~~

~~20. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder or disease selected from adrenocortical carcinoma, breast cancer, clear cell renal cell carcinoma (ccRCC), colorectal cancer, germ cell tumor , glioblastoma multiforme (GBM), glioma, head and neck cancer, hepatocellular carcinoma, kidney cancer, lung cancer, malignant glioma, ocular cancer, pancreatic cancer, paraganglioma, pheochromocytoma, prostate cancer, and renal cell carcinoma.~~

~~21. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament.~~

~~22. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a cancer.~~

~~23. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disorder or disease selected from adrenocortical carcinoma, breast cancer, clear cell renal cell carcinoma (ccRCC), colorectal cancer , germ cell tumor, glioblastoma multiforme (GBM), glioma, head and neck cancer , hepatocellular carcinoma, kidney cancer, lung cancer, malignant glioma, ocular cancer, pancreatic cancer, paraganglioma, pheochromocytoma, prostate cancer, and renal cell carcinoma.~~

15~~24~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] fumarate characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (24.9 ± 0.2)°, (6.2 ± 0.2)° and (20.9 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.

16~~25~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] fumarate characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (24.9 ± 0.2)°, (6.2 ± 0.2)°, (20.9 ± 0.2)°, (10.9 ± 0.2)° and (18.5 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.

17~~26~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] fumarate characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (24.9 ± 0.2)°, (6.2 ± 0.2)°, (20.9 ± 0.2)°, (10.9 ± 0.2)°, (18.5 ± 0.2)°, (22.8 ± 0.2)°, (12.9 ± 0.2)° and (16.1 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.

18~~27~~. The crystalline form according to any one of claims 15~~24~~ to 17~~26~~ characterized by having a thermogravimetric analysis curve showing a mass loss of not more than 0.4 weight% based on the weight of the crystalline form, when heated from 10 to 250 °C at a rate of 10 K/min.

19~~28~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] free form characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (9.7 ± 0.2)°, (18.4 ± 0.2)° and (19.4 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.

20~~29~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] free form characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (9.7 ± 0.2)°, (18.4 ± 0.2)°, (19.4 ± 0.2)°, (13.4 ± 0.2)° and (20.7 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.

21~~30~~. A crystalline form of (*S*)-1'-chloro-8-(difluoromethoxy)-8',8'-difluoro-6-(trifluoromethyl)-7',8'-dihydro-3*H*,6'*H*-spiro[imidazo[1,2-*a*]pyridine-2,5'-isoquinoline] free form characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of

(9.7 ± 0.2)°, (18.4 ± 0.2)°, (19.4 ± 0.2)°, (13.4 ± 0.2)°, (20.7 ± 0.2)°, (24.2 ± 0.2)°, (22.1 ± 0.2)° and (10.3 ± 0.2)°, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha1,2 radiation having a wavelength of 0.15406 nm.


2231. The crystalline form according to any one of claims 1928 to 2130 characterized by having a thermogravimetric analysis curve showing a mass loss of not more than 0.2 weight% based on the weight of the crystalline form, when heated from 10 to 250 °C at a rate of 10 K/min.

~~32. A compound according to any one of claims 24 to 31 or a pharmaceutically acceptable salt thereof, for use as a medicament.~~

2333. Use of a~~A~~ compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or a crystalline form according to any one of claims 15-22~~claim 32 or a pharmaceutically acceptable salt thereof~~, for ~~use in~~ the manufacture of a medicament for the treatment of ~~a disorder or disease is~~ a cancer**.**

2434. ~~A compound according to claim 33 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder or disease~~The use of claim 23, wherein the cancer is selected from adrenocortical carcinoma, breast cancer, clear cell renal cell carcinoma (ccRCC), colorectal cancer, germ cell tumor, glioblastoma multiforme (GBM), glioma, head and neck cancer, hepatocellular carcinoma, kidney cancer, lung cancer, malignant glioma, ocular cancer, pancreatic cancer, paraganglioma, pheochromocytoma, prostate cancer, and renal cell carcinoma**.**


2535. A process for producing the compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,


comprising the step of reacting the compound of formula (IV),



(IV)

or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof,


and the compound of formula (II),



(II)

or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof,

with a compound of formula (III)



(III)

or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof,

wherein

R^1 is F, Cl, Br, OCH_3, OCH_2F, $OCHF_2$, or OCF_3;

R^2 is F, Cl, CF_3, or CN;

X is $(CH_2)_{1\text{-}2}$, CHF, CHD, CD_2 or CF_2;

Y is $(CH_2)_{0\text{-}2}$, CHF, CHD, CD_2, O, S, OCH_2, or CF_2;

Z is CH_2, CD_2, CHF, CDF, CF_2, CH(OH), CO, $CH(CH_3)$, O, or S,

wherein, when Y is O, OCH_2, or S, then Z is CH_2;

wherein, when Z is O, S, or NCH_3, then Y is $(CH_2)_{0-2}$, or CF_2;

wherein, when Z is CH(OH), then Y is CHF or CF_2;

J is CR^J;

wherein R^J is H, F, Cl, Br, CH_3, CD_3, CF_3, CHF_2, CDF_2, OCH3 or CN;

E is CR^E or N;

wherein R^E is H, F, Cl, Br, I, CN, CH_3, CH_2CH_3, $CH(CH_3)_2$, , CD_3, CHD_2, CH_2D, CHF_2, CDF_2, $C(CH_3)F_2$, $C(CD3)F_2$, CF_3, cyclopropyl, OCH_3, OCH_2CH_2OH, OCF_3, SCH_3, $SCHF_2$,

G is CH or N; and

LG is a leaving group selected from F, Cl, or Br;

optionally in the presence of base selected from K_2CO_3 or Et_3N,

to obtain the compound of formula (1) or a pharmaceutically acceptable salt thereof.

26~~36~~. The process according to claim 25~~35~~, wherein the compound of formula (II) is cyclised with reagents selected from $SOCl_2$ in toluene, toluene sulfonyl chloride, or methanesulfonyl chloride, in the presence of a base selected from pyridine or Et_3N to give a compound of formula (I).